Gocovri Significantly Improves Dyskinesia and ‘Off’ Time in Parkinson’s, New Analysis Confirms

Gocovri Significantly Improves Dyskinesia and ‘Off’ Time in Parkinson’s, New Analysis Confirms
Parkinson’s disease patients treated with Gocovri (amantadine) experienced a 41 percent decrease in levodopa-induced dyskinesia compared to 14 percent of healthy people who took placebos. That analysis of two Phase 3 trials are summarized in the study “Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson’s Disease,” published in the journal CNS Drugs. “The results ... read more
Source: Parkinson’s News TodayPublished on 2018-03-22By Patricia Inacio, PhD